RxDoctor Payments Data

Kent Seitz, MD

Addiction Medicine · Charlotte, NCNPI 1467469320

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Orexo US, Inc. at 39.0% of the total.

$314in general payments, 2019–2025

Across 16 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Orexo US, Inc.$123
  • Avanir Pharmaceuticals, Inc.$45
  • Braeburn Inc.$36
  • Masimo Corporation$35
  • Otsuka America Pharmaceutical, Inc.$26
  • Indivior Inc.$17
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$314100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$314 in reported general payments places this provider in the 55th percentile of 42 addiction medicine providers in North Carolina.

See all addiction medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$23,847
Medicare patients
16
Services billed
223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SuboxoneBuprenorphine Hcl/Naloxone Hcl100$46,651
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl183$19,229
ZubsolvBuprenorphine Hcl/Naloxone Hcl14$8,165
Buprenorphine Hcl92$4,618
VyvanseLisdexamfetamine Dimesylate17$4,123
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine34$948
Clonazepam77$670
Gabapentin26$326
Lurasidone Hcl11$323
Alprazolam103$282
Eszopiclone13$253
Quetiapine Fumarate13$157
Paroxetine Hcl13$144
Diazepam26$118
Trazodone Hcl12$7

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Suboxone$17$46,651100 claims
Orexo US, Inc.Zubsolv$123$8,16514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 42 addiction medicine providers in North Carolina.

Other addiction medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →